Core Viewpoint - Viking Therapeutics' stock plummeted following the announcement of an oral obesity drug, while Amgen's new drug AMG 133 received clinical trial approval in China for heart failure with obesity [2][8]. Group 1: AMG 133 Overview - AMG 133 is an innovative bispecific antibody-peptide conjugate developed by Amgen, designed to inhibit the glucose-dependent insulinotropic polypeptide receptor (GIPR) and activate the glucagon-like peptide-1 receptor (GLP-1R), offering a unique mechanism of action [3][8]. - The drug has shown significant weight loss, blood sugar, insulin, and lipid improvements in preclinical studies involving obese mice and crab-eating macaques, along with enhanced satiety [4]. Group 2: Clinical Trial Results - In the Phase I trial (NCT04478708), AMG 133 demonstrated an average weight loss of 14.5% (approximately 26 pounds) in the high-dose group (420 mg, administered three times a month) [5]. - Notably, after discontinuation of the drug for 150 days, participants maintained an average weight loss of 11.2%, indicating lasting efficacy [5]. Group 3: Safety and Administration - The most common adverse reactions were mild to moderate gastrointestinal issues (nausea, vomiting), which typically resolved within 48 hours, indicating good overall tolerability [6]. - AMG 133's weight loss effect (14.5%) is superior to that of other drugs like terzepatide and semaglutide, particularly due to its convenient monthly dosing compared to the weekly administration of other medications [8].